Sanofi Appoints Muzammil Mansuri to Executive Committee and Executive Vice President, Strategy & Business Development
(Thomson Reuters ONE) -
Sanofi Appoints Muzammil Mansuri to Executive Committee and Executive Vice
President, Strategy & Business Development
Paris, France - February 5, 2016 - Sanofi announced the appointment of Muzammil
"Muz" Mansuri as a new member of the Executive Committee, effective February
22, 2016. Mr. Mansuri joins Sanofi from Gilead Sciences and will take the
position of Executive Vice President, Strategy & Business Development.
Mr. Mansuri will be responsible for all Group strategic planning, business
development, strategic intelligence, alliance management and the Sanofi Genzyme
Bio Ventures fund.
"Muz brings a wealth of experience as a senior executive within the global
biopharmaceutical industry," said Olivier Brandicourt, CEO, Sanofi. "Muz's deep
understanding of business development and strategy of global biopharmaceutical
organizations will allow him to contribute significantly to the overall Group
strategy and make him a valuable addition to Sanofi and the Executive
Committee."
A dual citizen of the U.S. and United Kingdom, Mr. Mansuri has more than 35
years of experience beginning in 1981 with Shell Research Limited where he began
as a research scientist. After Shell, he spent several years with Bristol-Myers
Company in various R&D roles with increasing responsibility. From 2007 to
2010, Mr. Mansuri was Chairman and CEO at CGI Pharmaceuticals. Mr. Mansuri's
most recently was Senior Vice President, Research & Development Strategy and
Corporate Development at Gilead Sciences.
Mr. Mansuri holds a Bachelor of Science degree in Chemistry and a Ph.D in
Organic Chemistry from the University College London. He held post-doctoral
positions at the University of California, Los Angeles (UCLA) and Columbia
University.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi has core strengths in
diabetes solutions, human vaccines, innovative drugs, consumer healthcare,
emerging markets, animal health and Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, as amended. Forward-looking statements
are statements that are not historical facts. These statements include
projections and estimates and their underlying assumptions, statements regarding
plans, objectives, intentions and expectations with respect to future financial
results, events, operations, services, product development and potential, and
statements regarding future performance. Forward-looking statements are
generally identified by the words "expects", "anticipates", "believes",
"intends", "estimates", "plans" and similar expressions. Although Sanofi's
management believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and uncertainties, many
of which are difficult to predict and generally beyond the control of Sanofi,
that could cause actual results and developments to differ materially from those
expressed in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other things, the
uncertainties inherent in research and development, future clinical data and
analysis, including post marketing, decisions by regulatory authorities, such as
the FDA or the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product candidates as well
as their decisions regarding labelling and other matters that could affect the
availability or commercial potential of such product candidates, the absence of
guarantee that the product candidates if approved will be commercially
successful, the future approval and commercial success of therapeutic
alternatives, the Group's ability to benefit from external growth opportunities,
trends in exchange rates and prevailing interest rates, the impact of cost
containment initiatives and subsequent changes thereto, the average number of
shares outstanding as well as those discussed or identified in the public
filings with the SEC and the AMF made by Sanofi, including those listed under
"Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements"
in Sanofi's annual report on Form 20-F for the year ended December 31, 2014.
Other than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or statements.
Contacts:
Media Relations Investor Relations
Laurence Bollack Sébastien Martel
Tel. : +33 (0)1 53 77 46 46 Tel.: +33 (0)1 53 77 45 45
mr(at)sanofi.com ir(at)sanofi.com
Press release (PDF):
http://hugin.info/152918/R/1983790/727153.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Sanofi via GlobeNewswire
[HUG#1983790]
Unternehmensinformation / Kurzprofil:
Datum: 05.02.2016 - 07:00 Uhr
Sprache: Deutsch
News-ID 448889
Anzahl Zeichen: 6312
contact information:
Town:
PARIS
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 286 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sanofi Appoints Muzammil Mansuri to Executive Committee and Executive Vice President, Strategy & Business Development"
steht unter der journalistisch-redaktionellen Verantwortung von
Sanofi (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
